Fluvoxamine in the treatment of panic disorder: A multi-center, double-blind, placebo-controlled study in outpatients

Gregory M. Asnis, Faiq A. Hameedi, Andrew W. Goddard, Steven G. Potkin, Donald Black, Mustaq Jameel, Kishore Desagani, Scott W. Woods

Research output: Contribution to journalArticle

68 Scopus citations

Abstract

Serotonergic mechanisms have been implicated in panic disorder, and several preliminary studies suggest that fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is helpful in its treatment. This 8-week double-blind parallel-group study compared fluvoxamine with a placebo in 188 patients with DSM-III-R defined panic disorder with or without agoraphobia. Efficacy assessments included a Daily Panic Attack Inventory, the Sheehan Disability Scale, the Clinical Anxiety Scale and the Clinical Global Impression Scale. When compared with the placebo, fluvoxamine produced highly significant improvements in most measures of the frequency and severity of panic disorder and in the more global aspects of disability and distress. Significant improvement was evident as early as week 1 for some panic variables. Fluvoxamine is a potent anti-panic agent with a relatively rapid onset of action.

Original languageEnglish (US)
Pages (from-to)1-14
Number of pages14
JournalPsychiatry Research
Volume103
Issue number1
DOIs
StatePublished - Aug 5 2001

    Fingerprint

Keywords

  • Agoraphobia
  • Anxiety
  • Selective serotonin reuptake inhibitor

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Asnis, G. M., Hameedi, F. A., Goddard, A. W., Potkin, S. G., Black, D., Jameel, M., Desagani, K., & Woods, S. W. (2001). Fluvoxamine in the treatment of panic disorder: A multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Research, 103(1), 1-14. https://doi.org/10.1016/S0165-1781(01)00265-7